Concurrent down-regulation of PTEN and NKX3.1 Expression in Iranian patients with prostate cancer

International Braz J Urol

Volumn 41, Issue 5, 2015, Pages 898-905

  Nodouzi, Vahideh ^a   Nowroozi, Mohammadreza ^b   Hashemi, Mehrdad ^c   Javadi, Gholareza ^a   Mahdian, Reza ^d  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Biological markers; NKX3 1 protein, human Supplementary Concept ; Prostatic neoplasms; PTEN phosphohydrolase; Real time polymerase chain reaction

Indexed keywords

GENETIC MARKER; HOMEODOMAIN PROTEIN; NKX3-1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

AGED; CARCINOGENESIS; DISEASE COURSE; DOWN REGULATION; GENE EXPRESSION; GENETIC MARKER; GENETICS; HUMAN; MALE; MIDDLE AGED; PROSTATE TUMOR; REAL TIME POLYMERASE CHAIN REACTION; REFERENCE VALUE; TEMPERATURE; TRANSITION TEMPERATURE; TWO DIMENSIONAL GEL ELECTROPHORESIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOGENESIS; DISEASE PROGRESSION; DOWN-REGULATION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION; GENETIC MARKERS; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; REAL-TIME POLYMERASE CHAIN REACTION; REFERENCE VALUES; TEMPERATURE; TRANSCRIPTION FACTORS; TRANSITION TEMPERATURE;

EID: 84950317097     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-5538.IBJU.2014.0036     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90. Erratum in: CA Cancer J Clin. 2011;61:134.
2. Baca SC, Garraway LA. The genomic landscape of prostate cancer. Front Endocrinol (Lausanne). 2012;3:69.
3. Ashida S, Nakagawa H, Katagiri T, Furihata M, Iiizumi M, Anazawa Y, et al. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res. 2004;64:5963-72.
4. Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol. 2010;34:1097-105.
5. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Young P, et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 1999;13:966-77.
6. Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, et al. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res. 1996;56:2411-6.
7. Voeller HJ, Augustus M, Madike V, Bova GS, Carter KC, Gelmann EP. Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res. 1997;57:4455-9. Erratum in: Cancer Res 1997;57:5613.
8. Magee JA, Abdulkadir SA, Milbrandt J. Haploinsufficiency at the Nkx3.1 locus. A paradigm for stochastic, dosagesensitive gene regulation during tumor initiation. Cancer Cell. 2003;3:273-83.
9. Asatiani E, Huang WX, Wang A, Rodriguez Ortner E, Cavalli LR, Haddad BR, et al. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res. 2005;65:1164-73.
10. No Authors. All cancers arise as a result of the aquisition of a series of fixed DNA sequence abnormalities, mutations, many of which ultimately confer a growth advantage upon. Available at. http://www.sanger.ac.uk/genetics/CGP/cosmic
11. Dahia PL. PTEN, a unique tumor suppressor gene. Endocr Relat Cancer. 2000;7:115-29.
12. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, et al. Cell autonomous role of PTEN in regulating castrationresistant prostate cancer growth. Cancer Cell. 2011;19:792-804.
13. Tsugawa K, Jones MK, Sugimachi K, Sarfeh IJ, Tarnawski AS. Biological role of phosphatase PTEN in cancer and tissue injury healing. Front Biosci. 2002;7:e245-51.
14. Fang J, Ding M, Yang L, Liu LZ, Jiang BH. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal. 2007;19:2487-97.
15. Kim MJ, CardiffRD, Desai N, Banach-Petrosky WA, Parsons R, Shen MM, et al. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A. 2002;99:2884-9.
16. Lei Q, Jiao J, Xin L, Chang CJ, Wang S, Gao J, et al. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell. 2006;9:367-78.
17. Nelson WG, De Marzo AM, DeWeese TL. The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention. Urology. 2001; 57(4 Suppl 1):39-45.
18. Grubb RL 3rd, Kibel AS. Prostate cancer: screening, diagnosis and management in 2007. Mo Med. 2007;104:408-13; quiz 413-4.
19. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010;24:1967-2000.
20. Madu CO, Lu Y. Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010;1:150-77.
21. Luo JH, Yu YP, Cieply K, Lin F, Deflavia P, Dhir R, et al. Gene expression analysis of prostate cancers. Mol Carcinog. 2002;33:25-35.
22. Figueiredo ML, Sato M, Johnson M, Wu L. Specific targeting of gene therapy to prostate cancer using a twostep transcriptional amplification system. Future Oncol. 2006;2:391-406.
23. Dong JT. Prevalent mutations in prostate cancer. J Cell Biochem. 2006;97:433-47.
24. Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK, Humphrey PA, et al. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol. 2002;22:1495-503.
25. Tanaka M, Komuro I, Inagaki H, Jenkins NA, Copeland NG, Izumo S. Nkx3.1, a murine homolog of Ddrosophila bagpipe, regulates epithelial ductal branching and proliferation of the prostate and palatine glands. Dev Dyn. 2000;219:248-60.
26. Bowen C, Gelmann EP. NKX3.1 activates cellular response to DNA damage. Cancer Res. 2010;70:3089-97.
27. Ouyang X, DeWeese TL, Nelson WG, Abate-Shen C. Loss-offunction of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res. 2005;65:6773-9.
28. Ornstein DK, Cinquanta M, Weiler S, Duray PH, Emmert-Buck MR, Vocke CD, et al. Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium. J Urol. 2001;165:1329-34.
29. Lind GE, Skotheim RI, Fraga MF, Abeler VM, Henrique R, Saatcioglu F, et al. The loss of NKX3.1 expression in testicular-and prostate-cancers is not caused by promoter hypermethylation. Mol Cancer. 2005;4:8.
30. Kunderfranco P, Mello-Grand M, Cangemi R, Pellini S, Mensah A, Albertini V, et al. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS One. 2010;5:e10547.